Facebook Tracking Image

National Comprehensive Cancer Network

Members Only
NCCN Oncology Research Program (ORP)
NCCN Lilly Abemaciclib Research Grant Opportunity: Submit by Friday, July 10, 2020
Study Proposal Submission-NCCN iEnvision
NCCN Pfizer Axitinib Research Grant Opportunity: Submit by Wednesday, August 12, 2020
NCCN Pfizer Biosimilars Grant Opportunity - Submit by Wednesday, September 9, 2020
ORP Recent News
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees
NCCN Policy Priorities

NCCN Research & Business Resources

Find a clinical trial >


In the late 1960s, a group of clinicians and scientists at UCLA came together to develop a cancer center they envisioned would become renowned for excellence in research, education and patient care. In 1976, the group received the highly regarded ‘comprehensive’ designation by the National Cancer Institute, launching the UCLA Jonsson Comprehensive Cancer Center (UCLA JCCC). Since then, the UCLA JCCC has focused on paradigm shifting fundamental research with translation to clinical applications, resulting in improved treatments for cancer patients, including numerous key frontline therapies and FDA approvals. Many examples of practice changing targeted therapeutics came from UCLA JCCC member science and translational activities. These include trastuzamab (Herceptin, 1998), gleevec (Imatinib, 2003), dasatinib (Sprycel, 2006), enzalutamide (Xtandi, 2012), palbociclib (Ibrance, 2015), axicabtagene ciloleucel (Yescarta, 2017), and apalutamide (Erleada, 2018). Our Center’s focus on therapeutics continues to this day with a total of eleven FDA approvals during the past five years, three of which originated from basic science bench research performed in the UCLA JCCC. More than 500 physicians and scientists are UCLA JCCC members, who together work to deliver the highest standards of excellence in cancer clinical care, research, prevention, education, and community service.

Clinical Care
The UCLA clinical cancer enterprise, consistently ranked as a “Best Hospital” in cancer by U.S. News & World Report, is comprised of two UCLA hospitals and numerous outpatient cancer clinics throughout Southern California. In addition to delivering the highest standard of medical, surgical and radiation oncology clinical care, the UCLA JCCC is committed to providing supportive care to cancer patients that extends far beyond diagnosis and treatment. An example of this commitment is the Simms/Mann-UCLA Center for Integrative Oncology, a national model of integrative oncology care for “when medicine alone is not enough”. The Simms/Mann Center’s highly trained staff of oncology social workers, psychologists, psychiatrics, integrative nutritionists, and other mind/body practitioners provide essential acute crisis and psycho-social support to patients and their families throughout the entire cancer trajectory. 
Clinical Research
Each year, UCLA physician-scientists conduct hundreds of cancer clinical trials. This robust clinical research enterprise enables moving discoveries from our laboratories through translation and into new cutting-edge treatments for cancer patients.  The UCLA JCCC Oncology Clinical Trials Network facilitates clinical research throughout the Los Angeles region, as well as nationally and internationally through our affiliated Translational Research in Oncology-US (TRIO-US) and TRIO-Global networks. This vibrant and robust clinical trials network infrastructure enables rapid accrual to cancer clinical trials, increasing the speed at which new cutting-edge treatments become available to cancer patients worldwide.
The UCLA JCCC has a long tradition of engagement with our diverse Los Angeles communities to reduce the cancer burden and address health disparities. Examples of this commitment include work to increase colorectal cancer screening in underserved populations, to reduce the use of tobacco products and lead policy initiatives to increase access to smoke-free rental housing in Los Angeles County, and initiatives to address the growing obesity epidemic which disproportionally affects our minority and underserved communities.
Training the next generation of physicians and scientists is at the core of our mission. We work to ensure that promising young investigators are identified early in their career and supported in a manner that enables them to reach their full potential. The UCLA JCCC relies on a constant influx of fresh ideas and perspectives to fuel the innovation that is one of our Center hallmarks. 
Research Programs
The UCLA JCCC operates six formal research programs to foster excellence in interdisciplinary collaboration within and between diverse subject areas. These programs include: Cancer and Stem Cell Biology; Cancer Molecular Imaging, Nanotechnology, and Theranostics; Epigenomics, RNA and Gene Regulation; Cancer Control and Survivorship; Signal Transduction and Therapeutics; and Tumor Immunology. UCLA also offers extensive shared resources to support our researchers in finding more effective ways to prevent, diagnose, and treat cancers of all types.